905273-36-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride is used as a starting material and building block for the synthesis of various pharmaceuticals. Its versatile chemical structure allows for the development of new drugs and therapeutic agents with potential applications in treating a wide range of diseases and medical conditions.
In the pharmaceutical industry, 3-BroMo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride is particularly valuable due to its ability to be modified and incorporated into diverse drug molecules. This makes it a crucial component in the discovery and development of innovative medications that can address unmet medical needs and improve patient outcomes.

Upstream product

• 905273-35-0 3-bromo-6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine 
• 27063-90-7 3-bromo-5,6-dimethylpyridine 
• 905273-34-9 5-bromo-2,3-bis (bromomethyl) pyridine 
• 583-61-9 2,3-Lutidine 
• 1356330-71-6 5-bromo-2,3-bis(hydroxymethyl)pyridine 
• 521980-82-5 5-bromopyridine-2,3-dicarboxylic acid dimethyl ester 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 

Downstream Products

• 1393546-06-9 3-bromo-6-(tert-butoxycarbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine 

Relevant academic research and scientific papers

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery

Using X-ray crystallographic screening, fragments 4 and 6 were identified as inhibitors of hematopoietic prostaglandin D2 synthase (H-PGDS). Both fragments induced a small protein movement in the X-ray crystal structure relative to the apo structure, where the highly polar nature of the ligand complemented the induced protein conformation. The manuscript describes the fragment optimisation of 4 and 6 followed by fragment growth to lead molecule 10. This showed favourable physicochemical properties and evidence of oral activity in blocking PGD2 generation in vivo.